Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Separation Of Sandoz, A Story Years In The Making

Proposed Spin From Novartis Set For 4 October, Following Years Of Conjecture

Executive Summary

Novartis’ shareholders last month voted yes on the proposal to separate Sandoz into a standalone generics and biosimilars firm. On the eve of the spin-off, Generics Bulletin looks back at a deal that was seemingly destined to happen sooner rather than later.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel